Australian Advisors Will Ponder Sandoz’ Pegfilgrastim And Pfizer’s Trastuzumab

 
• By Aidan Fry
  
Dollars
Australian reimbursement may be on the cards for Sandoz' Ziextenzo and Pfizer's Trazimera • Source: Shutterstock

More from Biosimilars

More from Products